# A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

> **NCT03150589** · PHASE3 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 705 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** SB11 (Proposed ranibizumab biosimilar)
- **DRUG:** Lucentis (ranibizumab)

## Key facts

- **NCT ID:** NCT03150589
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-14
- **Primary completion:** 2019-05-24
- **Final completion:** 2019-12-09
- **Target enrollment:** 705 (ACTUAL)
- **Last updated:** 2021-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150589, "A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03150589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*